Veristat

Executive Summary

Veristat is a full-service clinical research organization (CRO) and consultancy founded in 1994, headquartered in Paris, France. The company specializes in supporting the clinical development of novel and complex therapies, including drug delivery and digital health solutions. It integrates strategic planning, regulatory strategy, and clinical trial execution to help biopharmaceutical clients accelerate regulatory approvals while emphasizing scientific integrity and data quality. As a private company with a Phase 1/2 stage focus, Veristat positions itself as a partner for early-to-mid-stage clinical programs, leveraging over 30 years of experience in navigating complex regulatory pathways. Veristat operates in a competitive CRO market but differentiates through its specialization in novel therapies and its French origin, offering European expertise. While the company has no publicly disclosed financials or recent funding rounds, its long-standing presence suggests a stable client base and repeat business. The outlook for Veristat is tied to the broader growth of outsourced clinical services, particularly in digital health and drug delivery. However, as a private entity, visibility into upcoming milestones is limited, and the company's growth trajectory remains uncertain without public information on recent contract wins or regulatory achievements.